Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Yilmaz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2009 - 2012
- Marmara Univ- Fac MedClass of 2008
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2022 - 2027
- TN State Medical License 2022 - 2027
- GA State Medical License 2022 - 2026
- LA State Medical License 2022 - 2026
- WA State Medical License 2022 - 2026
- AL State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2019 Oct 22
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Start of enrollment: 2020 May 27
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Start of enrollment: 2018 Oct 31
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.Farhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, Guillermo Garcia-Manero, Musa Yilmaz
Blood Advances. 2025-05-13 - Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.Hannah Goulart, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D DiNardo
Cancer. 2025-04-15 - Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.Jayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, Indraneel Deshmukh, Gautam Borthakur
Bone Marrow Transplantation. 2025-04-11
Abstracts/Posters
- Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GOMusa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaMusa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant AbstractMusa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- MD Anderson Research Highlights: EHA 2022 Special EditionJune 8th, 2022
- Heavily Pre-Treated FLT3-Mutated AML Population May Benefit from Novel Triplet RegimenDecember 14th, 2021
- Data Show Sorafenib After Transplant Improves OS in FLT3-ITD AML, but Questions PersistNovember 30th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: